Ushbu ishga iqtibos qilgan ishlar

5 ta ish

Ish: Regulatory mechanisms of PD-1/PD-L1 in cancers

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Invisible influencers: the tumor microbiome’s impact on immunotherapy in colorectal cancer (CRC)

   Thabit Moath Omar, Ali Fawzi Al-Hussainy, S. Renuka Jyothi +8

   MaqolaCancer Research and TreatmentsExpert Review of Anticancer Therapy20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.002460

3. Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions

   Rasulbek Mashalov, Zulfizar Toshpulatova, Zhitong Chen +1

   MaqolaPlasma Applications and DiagnosticsScientific Reports20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.008635

4. Enhancing Immune Cell Activation through Cold Atmospheric Plasma: Disruption of PD-1/PD-L1/PD-L2 Immune Checkpoints via Molecular Dynamics

   Mashalov Rasulbek, Zulfizar Toshpulatova, Zhitong Chen +1

   PreprintPlasma Applications and DiagnosticsbioRxiv (Cold Spring Harbor Laboratory)20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.preprint.000051

5. Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies

   Hamzeh J. Al Ameer, Renuka Jyothi S, Israa Abdulhameed Ahmad +6

   MaqolaAutophagy in Disease and TherapyImmunology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.020141